Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Common Equity (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Common Equity for 3 consecutive years, with $36.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 79.36% to $36.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $36.8 million, a 79.36% decrease, with the full-year FY2024 number at $133.6 million, up 207.07% from a year prior.
  • Common Equity was $36.8 million for Q3 2025 at Inhibrx Biosciences, down from $68.6 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $219.4 million in Q2 2024 to a low of -$24.8 million in Q2 2023.
  • A 3-year average of $89.1 million and a median of $81.5 million in 2025 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 984.11% in 2024, then tumbled 79.36% in 2025.
  • Inhibrx Biosciences' Common Equity stood at $43.5 million in 2023, then surged by 207.07% to $133.6 million in 2024, then plummeted by 72.43% to $36.8 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Common Equity are $36.8 million (Q3 2025), $68.6 million (Q2 2025), and $94.4 million (Q1 2025).